The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis
- PMID: 30150034
- DOI: 10.1016/j.ejrad.2018.07.010
The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis
Abstract
Objectives: Radiologic surveillance after resection of pancreatic ductal adenocarcinoma (PDAC) can provide information on the extent and location of disease recurrence. This systematic review and meta-analysis aims to give an overview of the literature on the diagnostic performance of different imaging modalities for the detection of recurrent disease after surgery for PDAC.
Methods: A systematic search was performed in PubMed, EMBASE and Cochrane Library up to 20 December 2017. All studies reporting on the diagnostic value of imaging modalities for the detection of local and/or distant disease recurrence during follow-up after resection of PDAC were eligible. Both histologic confirmation of recurrent PDAC and clinical confirmation by disease progression on follow-up imaging were considered as suitable reference standard. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used for critical appraisal of methodological quality. Diagnostic accuracy data were extracted or calculated and presented in forest plots. A bivariate random-effects model was used to calculate pooled estimates of sensitivity and specificity.
Results: A total of seven retrospective studies with 333 relevant patients were ultimately eligible for data extraction. Overall, the methodological quality of the included studies was acceptable. All seven articles described test results of contrast-enhanced CT, whilst five and three articles reported outcomes on diagnostic accuracy of FDG PET-CT and FDG PET-CT combined with contrast-enhanced CT, respectively. For CT, pooled estimates for sensitivity were 0.70 (95% CI 0.61-0.78) and for specificity 0.80 (95% CI 0.69-0.88). For FDG PET-CT, pooled estimates for sensitivity and specificity were 0.88 (95% CI 0.81-0.93) and 0.89 (95% CI 0.80-0.94), respectively. For FDG PET-CT in combination with contrast-enhanced CT, pooled estimates for sensitivity were 0.95 (95% CI 0.88-0.98) and for specificity 0.81 (95% CI 0.63-0.92).
Conclusions: According to the current literature, post-operative CT has a moderate diagnostic accuracy in the detection of recurrent disease. FDG PET-CT imaging could be of additional value when disease recurrence is suspected despite negative or equivocal CT findings. Nevertheless, evidence supporting radiologic surveillance after resection of PDAC is limited. Future prospective studies are needed to optimize surveillance strategies after resection of pancreatic cancer.
Keywords: Diagnostic imaging; Follow-up studies; Pancreatectomy; Pancreatic neoplasms; Recurrence.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.J Nucl Med. 2015 Jul;56(7):995-1002. doi: 10.2967/jnumed.115.155580. Epub 2015 May 7. J Nucl Med. 2015. PMID: 25952733 Review.
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article. Review.
-
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.Abdom Radiol (NY). 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. Abdom Radiol (NY). 2018. PMID: 28900703
-
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2. Cochrane Database Syst Rev. 2021. PMID: 34753195 Free PMC article. Review.
-
Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.Nucl Med Commun. 2016 Nov;37(11):1180-8. doi: 10.1097/MNM.0000000000000573. Nucl Med Commun. 2016. PMID: 27428888 Review.
Cited by
-
Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX.Cancers (Basel). 2023 Oct 26;15(21):5151. doi: 10.3390/cancers15215151. Cancers (Basel). 2023. PMID: 37958326 Free PMC article.
-
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.J Clin Med. 2023 Oct 11;12(20):6461. doi: 10.3390/jcm12206461. J Clin Med. 2023. PMID: 37892599 Free PMC article. Review.
-
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel). 2023 Aug 28;13(9):1821. doi: 10.3390/life13091821. Life (Basel). 2023. PMID: 37763225 Free PMC article. Review.
-
Evaluation of the performance of and interobserver agreement on postoperative baseline CT findings in the identification of locoregional recurrence in patients with pancreatic ductal adenocarcinoma.Abdom Radiol (NY). 2023 Oct;48(10):3135-3146. doi: 10.1007/s00261-023-04012-x. Epub 2023 Jul 30. Abdom Radiol (NY). 2023. PMID: 37517056
-
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study.Cancers (Basel). 2023 May 17;15(10):2798. doi: 10.3390/cancers15102798. Cancers (Basel). 2023. PMID: 37345133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
